High-Risk Mucosal Human Papillomavirus 16 (HPV16) E6 Protein and Cutaneous HPV5 and HPV8 E6 Proteins Employ Distinct Strategies To Interfere with Interferon Regulatory Factor 3-Mediated Beta Interferon Expression

Juline Poirson (1) , Irina Paula Suarez (2) , Marie-Laure Straub (1) , Alexandra Cousido-Siah (2) , Paul Peixoto (3) , Eric Hervouet (3) , Anne Foster (1) , André Mitschler (2) , Noella Mukobo (1) , Yassmine Chebaro (2) , Dominique Garcin (4) , Sevda Recberlik (4) , Christian Gaiddon (4) , Danièle Altschuh (2) , Yves Nominé (2) , Alberto Podjarny (2) , Gilles Trave (2) , Murielle Masson (1)

1 BSC - Biotechnologie et signalisation cellulaire
2 IGBMC - Institut de Génétique et de Biologie Moléculaire et Cellulaire
3 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
4 STREINTH - Inserm U1113 - Equipe 2 "Réponse au Stress Cellulaire & Thérapies Innovantes" / "Stress Response & Innovative Therapies"

Persistent infection with some mucosal a-genus human papillomaviruses (HPVs; the most prevalent one being HPV16) can induce cervical carcinoma, anogenital cancers, and a subset of head and neck squamous cell carcinoma (HNSCC). Cutaneous b-genus HPVs (such as HPV5 and HPV8) associate with skin lesions that can progress into squamous cell carcinoma with sun exposure in Epidermodysplasia verruciformis patients and immunosuppressed patients. Here, we analyzed mechanisms used by E6 proteins from the aand b-genus to inhibit the interferon-b (IFNB1) response. HPV16 E6 mediates this effect by a strong direct interaction with interferon regulatory factor 3 (IRF3). The binding site of E6 was localized within a flexible linker between the DNAbinding domain and the IRF-activation domain of IRF3 containing an LxxLL motif. The crystallographic structure of the complex between HPV16 E6 and the LxxLL motif of IRF3 was solved and compared with the structure of HPV16 E6 interacting with the LxxLL motif of the ubiquitin ligase E6AP. In contrast, cutaneous HPV5 and HPV8 E6 proteins bind to the IRF3-binding domain (IBiD) of the CREB-binding protein (CBP), a key transcriptional coactivator in IRF3-mediated IFN-b expression. IMPORTANCE Persistent HPV infections can be associated with the development of several cancers. The ability to persist depends on the ability of the virus to escape the host immune system. The type I interferon (IFN) system is the first-line antiviral defense strategy. HPVs carry early proteins that can block the activation of IFN-I. Among mucosal a-genus HPV types, the HPV16 E6 protein has a remarkable property to strongly interact with the transcription factor IRF3. Instead, cutaneous HPV5 and HPV8 E6 proteins bind to the IRF3 cofactor CBP. These results highlight the versatility of E6 proteins to interact with different cellular targets. The interaction between the HPV16 E6 protein and IRF3 might contribute to the higher prevalence of HPV16 than that of other high-risk mucosal HPV types in HPV-associated cancers.

Mots clés: HPV; IRF3; interactomic; interferons; three-dimensional structure

Domaines: Sciences du Vivant [q-bio]

Juline Poirson, Irina Paula Suarez, Marie-Laure Straub, Alexandra Cousido-Siah, Paul Peixoto, et al.. High-Risk Mucosal Human Papillomavirus 16 (HPV16) E6 Protein and Cutaneous HPV5 and HPV8 E6 Proteins Employ Distinct Strategies To Interfere with Interferon Regulatory Factor 3-Mediated Beta Interferon Expression. Journal of Virology, 2022, 96, ⟨10.1128/jvi.01875-21⟩. ⟨hal-03766801⟩